

12. (Amended) A method for evaluating specificity of a drug comprising:

a) measuring activity of said drug against its target pathway to obtain a target activity

(D_{target});

b) measuring activity of said drug against at least one pathway other than said target pathway to obtain at least one off-target activity ($D_{off-target}$); and

c) determining said specificity by comparing said target activity and said off-target activity;

wherein said D_{target} and $D_{off-target}$ are based on measurements of a plurality of cellular constituents.

23. (Amended) A method of determining therapeutic index of a drug in a biological sample comprising:

determining said therapeutic index according to the formula: $[SI] TI = C_{target} / C_{off-target}$, wherein C_{target} is a minimum effective concentration needed to induce a threshold response in a target pathway and $C_{off-target}$ is the minimum toxic concentration needed to induce a threshold response in at least one off-target pathway.

24. (Amended) The method of claim 23 wherein said C_{target} and $C_{off-target}$ are measured according to a method comprising:

a) applying a plurality of levels of said drug to said biological sample and measuring a plurality of cellular constituents at each level of said drug in said biological sample to obtain a first profile of graded drug response;

b) applying said plurality of levels of said drug to a test sample, wherein said test sample is the same as said biological sample except that said target pathway is not functional, and measuring a plurality of cellular [constituents] constituents in said test sample at each level of said drug, to obtain a second profile of graded drug response; and

c) determining said C_{target} and $C_{off-target}$ by comparing said first and second profiles.

34. (Amended) A method of determining a therapeutic index of a drug in a biological sample comprising:

a) applying a plurality of levels of said drug to said biological sample;

B4
CONT.
b) determining a minimum effective concentration (C_{target}) needed to induce a threshold response in a target pathway, wherein said drug exerts its pharmacological activity through said target pathway;

c) determining a minimum toxic concentration ($C_{off-target}$) needed to induce a threshold response in at least one off-target pathway; and

d) determining said therapeutic index according to the formula: $[SI] TI = C_{target} / C_{off-target}$

target'

B5
36. (Amended) The method of claim 35 [herein] wherein said plurality of cellular constituents are transcripts of a plurality of genes.

Add new claims as follows:

B6
64. (New) A method for evaluating specificity of a drug, said method comprising:

(a) decomposing a drug response profile into one or a combination of pathway response profiles, wherein said drug response profile comprises measurements of a plurality of cellular constituents in a biological sample in response to said drug over a plurality of levels of drug exposure, and each said pathway response profile comprises measurements of a plurality of cellular constituents at a plurality of levels of perturbation to a biological pathway; and

(b) comparing, among said one or a combination of pathway response profiles, the pathway response profiles for the one or more biological pathways associated with therapeutic effects of the drug with the pathway response profiles for the one or more biological pathways that are associated with one or more non-therapeutic effects of the drug, thereby comparing activity of said drug on its target pathway (D_{target}) and at least one off-target pathway ($D_{off-target}$) and evaluating specificity of said drug.

65. (New) The method of claim 64, further comprising transforming said levels of drug exposure into said levels of perturbation by a horizontal scaling transformation.

66. (New) The method of claim 65, wherein said horizontal scaling transformation is a linear transformation.

67. (New) The method of claim 65, wherein said decomposing comprises determining said scaling transformation such that said drug response profile is represented by said one or a combination of pathway response profiles.

B6
cont.
68. (New) The method of claim 67, wherein said determining is by a method comprising least squares minimizing the residue between said drug response profile and said one or a combination of pathway response profiles.

69. (New) The method of claim 64, wherein values of said measurements of a plurality of cellular constituents have been converted into cellular constituent set values.

70. (New) A method for evaluating specificity of a drug, said method comprising decomposing a drug response profile into one or a combination of pathway response profiles, wherein said drug response profile comprises measurements of a plurality of cellular constituents in a biological sample in response to said drug over a plurality of levels of drug dosage, and each said pathway response profile comprises measurements of a plurality of cellular constituents at a plurality of levels of perturbation to a biological pathway, thereby evaluating specificity of said drug.

REMARKS

The subject application is a divisional application of Application Serial No. 09/222,582, filed on December 28, 1998.

The specification has been amended to correct typographical errors discovered by Attorneys for Applicants during review of the application. The specification has been amended to replace the word "perturbation" by the word "permutation" at page 30, lines 5 and 8, respectively. Support for this amendment is found in the specification at page 29, lines 24-25. The specification has also been amended to correct a typographical error in the identification of Fig. 8B. Support for this amendment is found in the specification at page 39, lines 30-31. The specification has also been amended to update the status of U.S. Patent Application Serial No. 09/074,983, now U.S. Patent No. 5,965,352. A marked version of the paragraphs in the specification which have been amended, with the amendments indicated by